protocolSection identificationModule nctId: NCT06368817, orgStudyIdInfo id: ACNS2321, briefTitle: Chemotherapy Followed by Response-Based Reduced Radiation Therapy for Patients With Central Nervous System Germinomas, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-04, primaryCompletionDateStruct date: 2033-11-04, completionDateStruct date: 2033-11-04, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Children's Oncology Group, class: NETWORK, descriptionModule briefSummary: A phase II trial that is attempting to build upon the excellent results of ACNS1123 stratum 2 by reducing the Radiotherapy (RT) dose for patients in a Complete Response (CR) after chemotherapy. The trial will be testing a further reduction in the whole ventricular irradiation (WVI) dose. Additionally, patients with metastatic disease and basal ganglia and thalamic germinoma will be included, and they will be treated with craniospinal irradiation (CSI) or whole brain irradiation (WBI) respectively., conditionsModule conditions: Intracranial Germ Cell Tumor, conditions: Childhood Central Nervous System Germinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 240, type: ESTIMATED, armsInterventionsModule interventions name: 3-Dimensional Conformal Radiation Therapy, interventions name: Carboplatin, interventions name: Etoposide, interventions name: Intensity-Modulated Radiation Therapy, outcomesModule primaryOutcomes measure: Event-free survival (EFS), secondaryOutcomes measure: Estimate the EFS distribution for eligible and evaluable patients in Stratum 2, secondaryOutcomes measure: To estimate the EFS distribution for eligible and evaluable patients in Stratum 3, secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Determine the impact of tumor location, treatment regimen and treatment modalities on the long-term neuroendocrine function for patients with CNS germinomas., secondaryOutcomes measure: Prospectively evaluate processing speed of children and young adults with CNS germinoma through the Children's Oncology Group (COG) Standardized assessment battery., otherOutcomes measure: EFS distribution for eligible and evaluable patients in Stratum 4 and Stratum 5., otherOutcomes measure: EFS distribution for eligible and evaluable patients in Stratum 6 and Stratum 7., otherOutcomes measure: prospectively collect blood, cerebrospinal fluid, and tumor tissue at diagnosis and second-look surgery (if feasible) for future biology studies., otherOutcomes measure: Incidence of cerebral vascular events (stroke or transient ischemic attacks) of children and young adults with CNS germinoma through the COG Standardized assessment battery: Patient-reported outcome measures, otherOutcomes measure: Incidence of cerebral vascular events (stroke or transient ischemic attacks) of children and young adults with CNS germinoma through the COG Standardized assessment battery: Health-reported quality of life, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 30 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False